The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | COMMANDER trial: iberdomide combinations to eliminate MRD after induction and autoSCT in myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents findings from the Phase I/II COMMANDER trial (NCT05434689), which aims to develop iberdomide-based combination therapies for use in the consolidation setting to achieve and sustain measurable residual disease (MRD) negativity in patients with multiple myeloma (MM) following autologous stem cell transplantation (autoSCT). The results of Phase I of the study were encouraging, and the trial is now in the dose expansion portion. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
